期刊文献+

结肠癌P53蛋白表达与临床病理的意义 被引量:5

P53 Protein Expression in Colorecatal Cancer and Its Relationship to Clinicopathological Course and Prognosis
下载PDF
导出
摘要 为了研究P53基因突变与结肠癌发生发展及预后的关系,对102例结肠癌、24例癌旁组织、16例正常结肠组织石蜡标本进行P53单抗的免疫组化染色.结果表明:结肠癌P53蛋白阳性率达70.6%,癌旁组织为20.8%,正常结肠组织中均无蛋白表达;阳性率间有显著的相关性(P<0.01),P53蛋白在高、中、低分化癌间阳性率有显著差异(阳性率分别为54.5%、72.7%、88.0%);在癌浸润深度肌层、浆膜层、浆膜外有显著差异(阳性率分别为53.8%、70.9%、90.5%);有无淋巴结转移的阳性率间亦有显著差异(为83.%、61.7%).P53蛋白的表达与结肠癌发生发展有关,表达强度与癌的分化程度、浸润深度、转移及预后有关.P53基因可作为评估患者预后的指标. In order to study the relationship of P53 gene mutation with the occurrence and prognosis of colorecatal cancer. Immunohistochemical method is used to examine paraffinembedd samples of 102 cancer, 24 nommaligant peri - tumoral tissue and 16 normal colorecatal tissues for overexpression of the P53 geate product. The P53 protein expression was high in 70.6% of colorecatal cancer,20.8% positive in tissues close to cancer. Normal tissue of colon showed negative expression of P53 protein. The positive rate of P53 was significantly higher in cancer than adjacent tissues or normal tissue( P 〈0.01). It was significantly difference in well, moderately and poorly differentiated adenocaeinomas(54.5%, 72.7% and 88.0%). The P53 protein is involved in the carcinogenesis if colorecatal cancer. The degree of P53 protein expession was significantly correlated with the degree of tumor cell differention ,invasion,metastasis and prognosis.
出处 《韶关学院学报》 2006年第3期87-88,140,共3页 Journal of Shaoguan University
关键词 结肠癌 P53 临床病理 免疫组化 colorecatal cancer P53 immunolohistochemistry clinical paphology prognosis
  • 相关文献

同被引文献20

  • 1狄建忠,郑起,赵中辛,樊友本,汪昱,史亚洲.P57^(kip2)与Ki67表达对结肠癌侵袭性的影响[J].肿瘤,2006,26(8):765-767. 被引量:6
  • 2廉朋,蔡国响,徐烨,蔡三军,师英强.PRL-3基因在结直肠癌原发灶中的表达及其临床意义[J].中国癌症杂志,2006,16(10):823-827. 被引量:2
  • 3Somasundaram K. Tumor suppressor p53: regulation and function [ J ]. Front Biosci, 2000,5:424-437.
  • 4Forones NM, Oshima C, Nanogaki S , et al. Determination of proliferative activity using ki67 and expression of p53 in colorectal cancer [ J ]. Arq Gastroenterol, 1999,36 : 122.
  • 5Schumaehcr U, Adam E, Fedhaus S, et al. Cell differention and chemosterapy influence p53 and MDM2 immunoreactivity in, human HT29 colon carcer cells grown in scid mice [ J]. Cancer Lett , 2001,166(2) :215-221.
  • 6VikhanskayaFD,Incalci M.P73 competes with P53 and attenuates its response in human ovarian cancer cell line[J].Nucleic Acids Res,2000,28:513-519.
  • 7Ruers T,Bleichrodt RP.Treatment of liver metastases,an update on the possibilities and results[J].Eur J Cancer,2002,38(7):1023-1033.
  • 8Borner MM.Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer-too good to be true?[J].Ann Oncol,1999,10(6):623-626.
  • 9Vikhanskaya F.D,Incalci M,Broggini M.p73 competes with p53 and attenuates its response in a human ovarian cancer cell line[J].Nucleic Acids Res,2000,28:513-519.
  • 10Van den Berg F M,Tigges A J,Schipper M E.Expression of the nuclear oncogene P53 in colon tumors[J].Pathology,1989,157:193.

引证文献5

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部